New study shows a single biopsy could provide enough molecular information to guide individualized therapy for prostate cancer patients
Feb. 29, 2016
| By Sabrina Richards / Fred Hutch News Service
A new study from scientists at Fred Hutchinson Cancer Research Center and the University of Washington suggests metastatic prostate cancer may present just the pair of characteristics needed for precision oncology: Metastases from different patients varied widely in their genetic characteristics, and metastases within a single patient were remarkably similar.
Center statistical analyses show screening for PSA velocity can lead to unnecessary biopsies
March 14, 2011
New research has shown that change in PSA levels over time—known as PSA velocity—is a poor predictor of prostate cancer and may lead to many unnecessary biopsies. The study findings were published online Feb. 24 in the Journal of the National Cancer Institute. Fred Hutchinson Cancer Research Center researcher, Cathee Till of the Public Health Sciences Division, conducted statistical analyses.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.